New HAE subtypes involving endothelial dysfunction support biomarker discovery and therapeutic strategies to stabilize the vascular barrier

This review addresses the evolving understanding of hereditary angioedema by discussing implications for biomarker discovery and therapeutic strategies aimed at stabilizing the endothelial barrier. The scope focuses on the mechanistic role of endothelial cells in vascular permeability rather than specific trial data or drug outcomes.

Increasing evidence indicates that endothelial cells play a decisive role in determining when and where vascular permeability occurs. This perspective shifts the focus from traditional bradykinin excess models to include direct endothelial regulatory pathways. The review highlights that newly identified HAE subtypes caused by pathogenic variants that directly affect endothelial regulatory pathways further support endothelial dysfunction as a key disease mechanism beyond bradykinin excess.

The authors do not report specific adverse events, sample sizes, or primary outcomes because these details were not reported in the source material. Consequently, the practice relevance is limited to conceptual frameworks rather than quantitative clinical guidance. The review suggests that future therapeutic strategies may need to target endothelial stabilization to address these newly recognized mechanisms.